Top 200 Drugs List: Brand, Generic and Class

The Top 200 drugs are the 200 generic medications that Medicare Part D paid the most claims for in 2024 — the drugs that cross a community pharmacy counter most often, and the list the PTCB Medications domain is built on. Every one of them is in the table below, ranked, with its leading US brand and the class it belongs to. This page says what "Top 200" actually means, how the list was built, and how to learn 200 names without memorizing them one at a time.

What "Top 200" means — a claim-count list, not a spending list

"Top 200" is a defined set, not a slogan. It is the 200 generic drugs with the highest claim counts in the 2024 Medicare Part D data, and the ranking is the whole definition: a drug is on the list because more prescriptions for it were filled than for the drug below it.

The choice of claims over dollars is deliberate, and it is the difference between a list you can study and a list you cannot. A spending list is dominated by a small number of specialty products — a drug with a five-figure price tag can top the money table on a few thousand patients, and a community pharmacy may never see it. A claim count asks the opposite question: what crosses the counter most often? That is what a pharmacy technician is asked to recognize, so that is what this list ranks.

The scale is worth holding onto, because it explains why the exam leans here. These 200 generics account for 1,510,824,757 Part D claims in 2024. Atorvastatin calcium, at the top, was filled 73,374,921 times; linagliptin, at #200, was filled 1,446,832 times. The cutoff is not an obscure drug — it is a diabetes medication a technician will meet in a normal week. Everything above it is more common still.

How the list was built (the sources)

The list is drawn from one published dataset and enriched from one public API, and both are re-runnable:

• The claim counts come from CMS's Medicare Part D Spending by Drug (data year 2024). Rows are the all-manufacturer roll-up — so a drug is counted once, not once per labeler — and Tot_Clms_2024 is summed by generic name across every brand CMS saw, then sorted descending.
• The brands and the classes come from the openFDA drug-label API and the NDC directory, read against each drug's own label. Every row's class is the label's Established Pharmacologic Class — the term FDA itself publishes — quoted rather than paraphrased. 130 of the 200 rows carry one; where FDA publishes none for a drug, the row says so instead of guessing.

Three consequences of that method are visible in the table, and each is a fact rather than an omission. First, 13 items CMS counts as claim lines are not drugs — test strips, lancets, pen needles, syringes, alcohol pads and their relatives — and they are excluded rather than ranked as medications. Second, where a drug is sold both over the counter and by prescription, the indication quoted is the teaching brand's own label, so the narrower wording is traceable. Third, the brand column is a teaching brand, not the only brand the drug has: a drug can carry many trademarked names, and the one printed here is the one a technician is most likely to hear.

The full row-by-row record — every brand's marketing status, the label indication, and the SPL set ID that lets any line be re-opened on the label itself — lives with the course's drug-list reference, and the same 200 rows are walked through in the medication names and classes guide.

How to learn the list — four passes, in this order

Two hundred names is too many to memorize as a flat list, and that is not what the exam asks anyway. PTCB's outline puts this material in Domain 1 as "Generic names, brand names, and classifications of medications" and "Indications of medications" — two directions of one fact. Learn the list as those directions, not as names:

1. Brand → generic, first. A patient, a prescriber or a label says the brand; the job starts by translating it to the nonproprietary name. This is the direction the counter runs in, so it is the direction to drill first.
2. Generic → class, second. The generic name is built from stems that were chosen to signal the family, so -olol is a beta blocker and -sartan is an ARB whether or not you have met the drug. The stem buys you the class without the brand.
3. Class → indication, third. Once a drug is placed in a class, its use is usually a consequence rather than a separate fact: a proton pump inhibitor reduces stomach acid, and the indication follows. This is the pass that turns recognition into answers.
4. The confusables, last. The pairs the eye swaps — a brand that looks like another brand, a drug that sounds like a class it is not — are the ones the exam uses to separate a reader who knows the list from one who has seen it.

Work the four passes in that order and the list stops being 200 things. It becomes a few dozen classes, each with a handful of members and one reason to be prescribed.

The 200, ranked by 2024 Medicare Part D claim volume

One row per drug: the rank by claims, the generic (nonproprietary) name, the teaching brand a technician is most likely to hear, and the class the two names point at. The class is the label’s own Established Pharmacologic Class wherever FDA publishes one; where it publishes none, the row carries the teaching class alone.

Three things the list is not

• It is not the whole pharmacopeia. These are the 200 most-claimed generics, and nothing else, so absence from this table says a drug is uncommon at the counter, not that it is unimportant.
• It is not fixed. The ranking is re-published every data year, and drugs move both ways as prescribing changes and as products lose exclusivity. The 2024 edition is what this course teaches; a later edition will re-order it.
• It is not a substitute for the class. A name learned without its class answers a recall question and misses the interaction, side-effect and storage questions that assume you know the family. The list is the entry point to Domain 1, not the whole of it.

Where to go next

The names in this list are the ground floor of the Medications domain, and the course takes them further in three steps:

• The full walk-through — the medication names and classes guide teaches the stems, the false friends and the class-to-indication table that hold these 200 rows together, then the topic's practice set turns them into brand-to-generic and class-to-use questions, easiest-first, each with a full explanation.
• What happens when two of them meet — drug interactions and side effects takes the classes here and asks about the combinations.
• The exam they are being learned for — what score you need to pass, how many questions the exam has, and whether the PTCB exam is hard cover the test itself.

PTCE® is a registered trademark of the Pharmacy Technician Certification Board (PTCB). Elk Ridge Academy is not affiliated with or endorsed by PTCB.